{"schema_version":"secwatch.filing_event.v1","accession":"0000929638-24-001326","form_type":"8-K","ticker":null,"cik":"0001100397","company_name":"Ayala Pharmaceuticals, Inc.","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.283758+00:00","generated_at":"2026-06-04T02:43:06.990773+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ayala Pharmaceuticals' CMO departs immediately; CFO agrees to leave June 25","bullets":["Andres Guttierez, CMO and EVP, departed on March 25, 2024 upon closing of asset sale to Immunome.","Roy Golan, CFO, agreed to depart on June 25, 2024, per agreement dated March 27, 2024.","No replacements have been named for either departing officer.","Departures follow the previously announced Asset Purchase Agreement with Immunome, Inc."],"urls":{"canonical":"https://secwatch.observer/filing/0000929638-24-001326","json":"https://secwatch.observer/filing/0000929638-24-001326.json","markdown":"https://secwatch.observer/filing/0000929638-24-001326.md","text":"https://secwatch.observer/filing/0000929638-24-001326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100397/000092963824001326/0000929638-24-001326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100397/000092963824001326/a8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:43:06.990773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"48f66d1eae","claim":"Roy Golan departed as Chief Financial Officer at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"the Company and Roy Golan, the Company’s Chief Financial Officer, agreed that Mr. Golan would depart the Company on June 25, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100397/000092963824001326/0000929638-24-001326-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"f7a69b0e83","claim":"Andres Guttierez departed as Chief Medical Officer and Executive Vice President at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Andres Guttierez, the Company’s Chief Medical Officer and Executive Vice President, departed the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100397/000092963824001326/0000929638-24-001326-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Medical Officer and Executive Vice President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}